Kodiak Sciences Inc.

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-VEGF antibody biopolymer that has completed Phase 3 clinical studies for high prevalence retinal vascular diseases. KSI-301 is also being studied in Phase 3 trials for diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in a Phase 2/3 study for wet AMD. Additionally, the company has preclinical candidates including KSI-501, an anti-IL-6 and VEGF-trap bispecific antibody biopolymer conjugate, and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF for patients with retinal fluid and inflammation.

Kodiak Sciences Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol KOD. The company's shares are traded in United States Dollars (USD). As a US-based company listed on a major US exchange, its stock is accessible to investors through standard brokerage accounts that offer Nasdaq trading.

Kodiak Sciences Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of novel therapies, particularly for retinal diseases. The company's work involves advanced biopolymer conjugates and bispecific antibodies, placing it at the intersection of drug discovery and ophthalmic therapeutics.

Kodiak Sciences Inc. is headquartered in Palo Alto, California, United States. The company was originally founded as Oligasis, LLC and rebranded to Kodiak Sciences Inc. in September 2015. It was incorporated in 2009. The company's operations are primarily based in the US, and it focuses on developing treatments for retinal diseases, a significant area of unmet medical need globally.

Kodiak Sciences Inc.'s main product candidate is tarcocimab tedromer (KSI-301), an anti-VEGF antibody biopolymer that has completed Phase 3 clinical studies for retinal vascular diseases. It is being investigated for diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema. The company also has preclinical candidates: KSI-501, an anti-IL-6 and VEGF-trap bispecific antibody biopolymer conjugate for retinal vascular diseases, and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF for patients with retinal fluid and inflammation. These candidates aim to address high prevalence retinal conditions.